文献速递湿疹皮炎与荨麻疹

特应性皮炎系统性糖皮质激素使用及危害的理赔数据分析

Utilization and related harms of systemic glucocorticosteroids for atopic dermatitis: claims data analysis.
PubMed 文献 · Br J Dermatol · 2024-01-01

该研究基于德国法定健康保险理赔数据,分析特应性皮炎(AD)患者系统性糖皮质激素(SGC)的使用情况及潜在危害。2020年AD患病率为4.07%,9.91%的AD患者被处方SGC,高于无AD者的5.54%(P<0.01)。长期随访显示58%使用SGC的AD患者在超过一个季度内被处方SGC,15%超过六个季度;频繁处方SGC者骨质疏松和糖尿病的发生风险显著升高。

要点

  • AD患者SGC处方率显著高于无AD者(9.91% vs 5.54%,P<0.01)。
  • 58%使用SGC的AD患者在3年内超过一个季度被处方SGC,15%超过六个季度。
  • 频繁处方SGC的AD患者骨质疏松和糖尿病风险显著增加。

核心结论

  • 德国大量AD患者被长期处方SGC,频繁使用与骨质疏松和糖尿病等已知激素危害的发生率显著升高相关,提示需优化医疗。

研究设计与样本

  • 基于德国法定健康保险全国性大型数据库的横断面和纵向分析,分析SGC处方及预设合并症发生率,并按年龄、性别和发病率调整比较。

主要发现

  • 2020年AD患病率为4.07%(女性4.12%,男性3.42%)。
  • AD患者中9.91%被处方SGC,无AD者为5.54%(P<0.01)。
  • 女性SGC处方率显著高于男性(10.20% vs 9.42%,P<0.01),老年人中更高,且存在地区差异。
  • 3年随访中,58%使用SGC的AD患者在超过一个季度内被处方SGC,15%在超过六个季度内被处方。
  • 频繁处方SGC的AD患者发生骨质疏松的OR为3.90(定义1)和1.80(定义2),糖尿病的OR为1.90(定义1)和1.38(定义2),均显著高于少处方组。

关键数值与推荐

  • SGC使用量化定义1:至少一个季度有SGC处方的季度数;定义2:限定日剂量(DDD)。

临床怎么用

  • 临床应限制AD患者SGC的长期使用,频繁处方者需监测骨质疏松和糖尿病等不良反应,并考虑使用获批的长期治疗药物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Systemic glucocorticosteroids (SGCs) are used in the short-term treatment of atopic dermatitis (AD), but are not recommended for long-term use because they are associated with severe side-effects. OBJECTIVES: This study aimed to characterize the utilization and potentially negative effects of SGC use for AD in German statutory health insurance (SHI) claims data. METHODS: Cross-sectional and longitudinal analysis of a large nationwide SHI dataset. SGC drug prescriptions and incidences of predefined comorbidities after drug initiation that were known to be potentially harmful side-effects were analysed. SGC use was quantified by (-definition 1) the number of quarters with at least one SGC prescription and (definition 2) the defined daily doses (DDD). Comparisons were adjusted for age, sex and morbidity. RESULTS: The AD prevalence was 4.07% in 2020 (4.12% women, 3.42% men). During this period 9.91% of people with AD were prescribed SGCs compared with 5.54% in people without AD (P < 0.01). Prescribing of SGCs was significantly higher in women (10.20% vs. 9.42% in men, P < 0.01) and in the elderly. AD and SGC prevalence varied regionally. In a 3-year follow-up period, 58% of people with AD receiving a SGC were prescribed SGCs in > one quarter and 15% in > six quarters. The odds of developing osteoporosis [odds ratio (OR) 3.90 -(definition 1) and 1.80 (definition 2)] and diabetes [OR 1.90 (definition 1) and 1.38 (definition 2)] were significantly higher in people with AD on SGCs, especially in the frequently prescribed group compared with the rarely prescribed group, regardless of quantified use. CONCLUSIONS: A considerable number of people with AD in Germany are prescribed long-term SGCs. The onset of medical conditions known to be harmful effects of steroids was significantly more frequent in those who were frequently prescribed SGCs, indicating the need for optimized healthcare. Atopic dermatitis (AD) is a condition that causes severe itching and dry skin. AD is common and affects almost 100 000 people in Germany. The treatment for AD with systemic glucocorticosteroids (SGCs) should be limited to short-term use, typically lasting up to 3 weeks during periods of acute flares. This study aimed to investigate how often and for how long people with AD in Germany use SGCs and whether there are any adverse effects associated with their use, using data from health insurance claims. We found that a significant number of people with AD were frequently prescribed SGCs for prolonged periods of time, which could increase the risk of side-effects such as osteoporosis, diabetes, gastritis, depression and oesophageal reflux. Overall, our study findings highlight the importance of reducing the overuse of SGCs and advocate the use of approved long-term medications for people with AD, to reduce the risks of harmful side-effects.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Hagenström K, Klinger T, Müller K, et al. Utilization and related harms of systemic glucocorticosteroids for atopic dermatitis: claims data analysis. Br J Dermatol. 2024. PMID: 38924726. doi:10.1093/bjd/ljae250

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。